You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Renal Therapeutic Angiogenesis Using the Novel Biologic ELP-VEGF

    SBC: LEFLORE TECHNOLOGIES LLC            Topic: 400

    Abstract.Chronic kidney disease (CKD) is a progressive disorder affecting almost 14% of the general population, and this disease has shown a relentless growth over the past 2 decades. Patients with CKD have higher rates of hospitalization, greater mortality, shorter life expectancy, and their healthcare costs are up to 5 times more expensive than non-CKD patients. Thus, treatments to slow, halt, o ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Improving treatment options and outcomes in fungal keratitis

    SBC: TranZ Biosciences LLC            Topic: N

    ABSTRACT Fungal keratitisprimarily caused by CandidaFusariumor Aspergillus speciesis a leading cause of blindness among corneal diseasesAmphotericin BAmBremains the gold standard in the treatment of Candida keratitis and is also the fallback option for other corneal fungal infectionsAlthough widely used off label in ocular infectionsophthalmic AmB formulations are not available commerciallyThe com ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Process for GMP Production of Natural THC and CBD

    SBC: ElSohly Laboratories, Incorporated            Topic: R41

    Development Process for Production of Natural THC and CBD AbstractTetrahydrocannabinolTHCand cannabidiolCBDare two major constituents of the cannabis plant that have pharmacological properties with potential therapeutic value in several disease conditionsWhileTHC has already been in use clinically for two indicationsnausea and vomiting in cancer patients receiving chemotherapy and appetite stimula ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. An Opioid/Cannabinoid Analgesic that Boosts Pain Relief and Blocks Opiate Reward

    SBC: ElSohly Laboratories, Incorporated            Topic: NIDA

    Project Summary Abuse of prescription opioids and fatalities related to their misuse have increased sharply in recent yearsmaking the development of pain medications with reduced abuse potential a major public health priorityWhen combinedopioids and cannabinoidCBreceptor agonists show analgesic effects appear to be at least additive in a number of pain modelsCannabidiolCBDalthough much less psycho ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. A Preclinical Trial of Therapeutic Angiogenesis Plus Angioplasty and Stenting for Renal Vascular Disease

    SBC: LEFLORE TECHNOLOGIES LLC            Topic: 400

    Abstract Chronic kidney disease CKD is a progressive disorder affecting almost of the general population and this disease has shown a relentless growth over the past decades Patients with CKD have higher rates of hospitalization greater mortality shorter life expectancy and their healthcare costs are up to times more expensive than non CKD patients Thus treatments to slow halt ...

    STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health
  6. Bioassay Methods for Standardization of Immune Enhancing Dietary Supplements

    SBC: PSI (Phytochemical Services, Incorporated)            Topic: 213

    DESCRIPTION provided by applicant Clinical trials testing the potential health benefits of immune enhancing dietary supplements have produced inconsistent results A major problem contributing to these inconsistent outcomes is that these studies have used a wide variety of poorly characterized products Attempts to solve this product quality control problem using chemical standardization method ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Orally Active Formulations of DHA Dimers for the Treatment of Infectious Diseases

    SBC: ElSohly Laboratories, Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): The natural product artemisinin is a sesquiterpene endoperoxide with known anti-malarial activity against both chloroquine-sensitive and chloroquine-resistant strains of the parasite Plasmodium falciparum. In addition to its anti-malarial activity, artemisinin was reported to have cytotoxic activity against several different tumor cell lines. Recently, artemisi ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Development of Tetrahydrocannabinol Prodrugs for Topical Treatment of Glaucoma

    SBC: ElSohly Laboratories, Incorporated            Topic: NEI

    DESCRIPTION (provided by applicant): Currently, FDA approved clinical applications of 9-Tetrahydrocannabinol (THC) include control of nausea and vomiting associated with chemotherapy and for appetite stimulation for AIDS patients suffering from anorexia and wasting syndrome. However, THC also has significant potential in the treatment of glaucoma, the second largest cause of blindness, by dec ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Thermally Targeted Delivery of Therapeutic Peptides

    SBC: Thermally Targeted Therapeutics, Incorporated            Topic: N/A

    DESCRIPTION (provided by applicant): Current treatment of solid tumors is limited by normal tissue tolerance, inherent tumor resistance to radiation or chemotherapy, and toxicity from systemic administration of antineoplastic agents. The result is a narrow therapeutic index for most current chemotherapeutic agents. Our long term goal is to overcome these limitations by developing a targeted therap ...

    SBIR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health
  10. Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

    SBC: ElSohly Laboratories, Incorporated            Topic: N/A

    DESCRIPTION (provided by applicant): Poison ivy/oak contact dermatitis is the most prevalent skin allergy in the United States, affecting gt50% of the adult population. The condition is the major cause of occupational hazard among outdoor workers in forestry, agriculture and firefighting, resulting in significant medical expenses and workers disability. Attempts have been made to provide prophyla ...

    STTR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government